Joshua Reed Biography and Net Worth

Director of Scholar Rock

Joshua Reed has served as a member of our board of directors since March 2021. Mr. Reed previously served as Chief Financial Officer of Omega Therapeutics, Inc. from May 2022 to May 2024 where he was responsible for finance, investor relations, and information technology.From July 2018 until May 2022, Mr. Reed served as Chief Financial Officer of Aldeyra Therapeutics, Inc., where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb’s (“BMS”) United States and Puerto Rico operations, a $12 billion business unit. Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an MBA from the University of Michigan’s Ross School of Business.

What is Joshua Reed's net worth?: The estimated net worth of Joshua Reed is at least $712.06 thousand as of May 29th, 2025. Mr. Reed owns 15,732 shares of Scholar Rock stock worth more than $712,062 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Reed may own. Learn More about Joshua Reed's net worth.
How do I contact Joshua Reed?: The corporate mailing address for Mr. Reed and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Joshua Reed's contact information.
Has Joshua Reed been buying or selling shares of Scholar Rock?: Joshua Reed has not been actively trading shares of Scholar Rock over the course of the past ninety days. Most recently, Joshua Reed sold 5,400 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.72, for a transaction totalling $160,488.00. Following the completion of the sale, the director now directly owns 15,732 shares of the company's stock, valued at $467,555.04. Learn More on Joshua Reed's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 10/6/2025.

Joshua Reed Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/29/2025	Sell	5,400	$29.72	$160,488.00	15,732

Joshua Reed Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $45.20

$42.83

$45.50

50 Day Range

MA: $34.97

$27.92

$45.20

2 Week Range

Now: $45.20

$22.71

$46.98

Volume

1,340,235 shs

Average Volume

2,069,553 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61